Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Nuwellis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NUWE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: NUWE's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: NUWE underperformed the US Medical Equipment industry which returned 31% over the past year.
Return vs Market: NUWE underperformed the US Market which returned 39.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Nuwellis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Nuwellis undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NUWE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NUWE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NUWE is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: NUWE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NUWE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NUWE is good value based on its PB Ratio (1x) compared to the US Medical Equipment industry average (4.5x).
How is Nuwellis forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NUWE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NUWE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NUWE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NUWE's revenue (39.5% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: NUWE's revenue (39.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NUWE's Return on Equity is forecast to be high in 3 years time
How has Nuwellis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NUWE is currently unprofitable.
Growing Profit Margin: NUWE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NUWE is unprofitable, but has reduced losses over the past 5 years at a rate of 1.1% per year.
Accelerating Growth: Unable to compare NUWE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NUWE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (20%).
Return on Equity
High ROE: NUWE has a negative Return on Equity (-54.33%), as it is currently unprofitable.
How is Nuwellis's financial position?
Financial Position Analysis
Short Term Liabilities: NUWE's short term assets ($32.1M) exceed its short term liabilities ($3.2M).
Long Term Liabilities: NUWE's short term assets ($32.1M) exceed its long term liabilities ($48.0K).
Debt to Equity History and Analysis
Debt Level: NUWE is debt free.
Reducing Debt: NUWE has no debt compared to 5 years ago when its debt to equity ratio was 89.7%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NUWE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NUWE has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 6% each year.
What is Nuwellis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NUWE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NUWE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NUWE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NUWE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NUWE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nestor Jaramillo (64 yo)
Mr. Nestor Jaramillo, Jr. has been President of Nuwellis, Inc. (formerly known as CHF Solutions, Inc.) since July 1, 2020 and has been its Chief Executive Officer and Director since January 16, 2021. He se...
CEO Compensation Analysis
Compensation vs Market: Nestor's total compensation ($USD481.14K) is about average for companies of similar size in the US market ($USD544.90K).
Compensation vs Earnings: Nestor's compensation has been consistent with company performance over the past year.
Experienced Management: NUWE's management team is considered experienced (2 years average tenure).
Experienced Board: NUWE's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 397.3%.
Nuwellis, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Nuwellis, Inc.
- Ticker: NUWE
- Exchange: NasdaqCM
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$29.394m
- Shares outstanding: 6.53m
- Website: https://www.nuwellis.com
Number of Employees
- Nuwellis, Inc.
- 12988 Valley View Road
- Eden Prairie
- United States
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company’s products are the Aquadex FlexFlow and Aqua...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/24 23:37|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.